Αρχική World News Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of... World News Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Από Ogkologos - 27 Απριλίου, 2026 295 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Respuestas a sus preguntas sobre la vacuna contra el COVID-19 12 Μαρτίου, 2021 Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board,... 18 Οκτωβρίου, 2024 How Early Cancer Detection and Diagnosis Saved My Life Twice: A... 27 Δεκεμβρίου, 2023 Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome? 19 Απριλίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Cancer Prevention Message Is Key for HPV Vaccination Discussions with Parents Sugar Compound Found in Breast Milk May Help Ease Chemotherapy Side... Los ensayos clínicos y las personas mayores, con Dr. Enrique Soto Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated...
